|
1
|
Jackson TM, Bittman M and Granowetter L:
Pediatric malignant bone tumors: A review and update on current
challenges, and emerging drug targets. Curr Probl Pediatr Adolesc
Health Care. 46:213–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ballatori SE and Hinds PW: Osteosarcoma:
Prognosis plateau warrants retinoblastoma pathway targeted therapy.
Signal Transduct Target Ther. 1:160012016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botter SM, Neri D and Fuchs B: Recent
advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hattinger CM, Fanelli M, Tavanti E, Vella
S, Ferrari S, Picci P and Serra M: Advances in emerging drugs for
osteosarcoma. Expert Opin Emerg Drugs. 20:495–514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seeler JS and Dejean A: SUMO and the
robustness of cancer. Nat Rev Cancer. 17:184–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
David R: Sumoylation: Targeting SUMO. Nat
Rev Mol Cell Biol. 11:3872010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li XC, Zeng Y, Sun RR, Liu M, Chen S and
Zhang PY: SUMOylation in cardiac disorders-a review. Eur Rev Med
Pharmacol Sci. 21:1583–1587. 2017.PubMed/NCBI
|
|
8
|
Guo C and Henley JM: Wrestling with
stress: Roles of protein SUMOylation and deSUMOylation in cell
stress response. IUBMB Life. 66:71–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bawa-Khalfe T and Yeh ET: SUMO losing
balance: SUMO proteases disrupt SUMO homeostasis to facilitate
cancer development and progression. Genes Cancer. 1:748–752. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH and Baek SH: Emerging roles of
desumoylating enzymes. Biochim Biophys Acta. 1792:155–162. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang K and Zhang XC: Inhibition of SENP5
suppresses cell growth and promotes apoptosis in osteosarcoma
cells. Exp Ther Med. 7:1691–1695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mikolajczyk J, Drag M, Békés M, Cao JT,
Ronai Z and Salvesen GS: Small ubiquitin-related modifier
(SUMO)-specific proteases: Profiling the specificities and
activities of human SENPs. J Biol Chem. 282:26217–26224. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chiu SY, Asai N, Costantini F and Hsu W:
SUMO-specific protease 2 is essential for modulating p53-Mdm2 in
development of trophoblast stem cell niches and lineages. PLoS
Biol. 6:e3102008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen HJ, Zhu HY, Yang C and Ji F: SENP2
regulates hepatocellular carcinoma cell growth by modulating the
stability of β-catenin. Asian Pac J Cancer Prev. 13:3583–3587.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang QF, Tian YW, Shen Q, Xue HZ and Li
K: SENP2 regulated the stability of β-catenin through WWOX in
hepatocellular carcinoma cell. Tumour Biol. 35:9677–9682. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen L, Pei H, Lu SJ, Liu ZJ, Yan L, Zhao
XM, Hu B and Lu HG: SPOP suppresses osteosarcoma invasion via
PI3K/AKT/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci.
22:609–615. 2018.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jo A, Denduluri S, Zhang B, Wang Z, Yin L,
Yan Z, Kang R, Shi LL, Mok J, Lee MJ and Haydon RC: The versatile
functions of Sox9 in development, stem cells, and human diseases.
Genes Dis. 1:149–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Chen Y, Zhou F, Jie L, Pu L, Ju J,
Li F, Dai Z, Wang X and Zhou S: Sox9 regulates hyperexpression of
Wnt1 and Fzd1 in human osteosarcoma tissues and cells. Int J Clin
Exp Pathol. 7:4795–4805. 2014.PubMed/NCBI
|
|
20
|
Gill G: SUMO changes Sox for developmental
diversity. Mol Cell. 20:495–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hattori T, Kishino T, Stephen S,
Eberspaecher H, Maki S, Takigawa M, de Crombrugghe B and Yasuda H:
E6-AP/UBE3A protein acts as a ubiquitin ligase toward SOX9 protein.
J Biol Chem. 288:35138–35148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oh HJ, Kido T and Lau YF: PIAS1 interacts
with and represses SOX9 transactivation activity. Mol Reprod Dev.
74:1446–1455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lefebvre V and Dvir-Ginzberg M: SOX9 and
the many facets of its regulation in the chondrocyte lineage.
Connect Tissue Res. 58:2–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan MY, Mu XY, Liu B, Wang Y, Bao ED, Qiu
JX and Fan Y: SUMO-specific protease 2 suppresses cell migration
and invasion through inhibiting the expression of MMP13 in bladder
cancer cells. Cell Physiol Biochem. 32:542–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu XY, Liu Z, Zhang KL, Feng J, Liu XF,
Wang LY and Wang ZW: SUMO-specific protease 2-mediated
deSUMOylation is required for NDRG2 stabilization in gastric cancer
cells. Cancer Biomark. 21:195–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan M, Zhang D, Zhang E, Xu D, Liu Z, Qiu
J, Fan Y and Shen B: SENP2 suppresses epithelial-mesenchymal
transition of bladder cancer cells through deSUMOylation of
TGF-βRI. Mol Carcinog. 56:2332–2341. 2017. View Article : Google Scholar : PubMed/NCBI
|
